Rutas glucometabólicas alteradas en pacientes infectados con SARS-CoV-2: Altered glyco-metabolic pathways in patients infected with SARS-CoV-2

• Autores: Mejía-Nureña, Doris Ysabel, Leiva-Reyes, Cinthya Lizbeth, Ibañez-Lara, Elizabeth Jireh, Polo-Mejía, Sharon Marlit, Gil-Reyes, William Martín
• Formato: artículo
• Fecha de Publicación: 2022
• Institución: Universidad Nacional de Trujillo
• Repositorio: Revistas - Universidad Nacional de Trujillo
• Lenguaje: español
• OAI Identifier: oai:ojs.revistas.unitru.edu.pe:article/4263
• Enlace del recurso: https://revistas.unitru.edu.pe/index.php/RMT/article/view/4263
• Nivel de acceso: acceso abierto
• Materia: glucose; blood glucose; hyperglycemia; hypoxia; COVID-19; SARS-CoV-2; glucosa; glucemia; hiperglucemia; hipoxia

In SARS-CoV-2 virus infection, HIF-1 overexpression drives a glycolysis-dependent metabolic change for increased cell proliferation and cytokine synthesis in various cells and tissues; Furthermore, due to the insufficient amount of ATP, various metabolic pathways that induce hyperglycemia are accelerated; an indicator of poor prognosis and high mortality in patients without a previous diagnosis of diabetes. Hyperglycemia is the result of oxidative stress-induced insulin resistance and increased glycolysis, as well as dysregulation of hormones such as glucagon, growth hormone, glucocorticoids, and insulin; whose synthesis decreases due to the transdifferentiation of beta cells. These hyperglycemic and hypoglycemic conditions have been associated, in COVID-19 patients, with new-onset diabetes, cardiomyocyte damage, and other cardiac problems with lung deterioration; as well as the presence of acute kidney injury and hypometabolism of glucose in the brain.